Perfuze Announces Completion of Enrollment in Pivotal US Clinical Study and Appointment of Joe Rotger as Executive Vice President of Sales
GALWAY, Ireland--(BUSINESS WIRE)-- Perfuze, a leader in next-generation catheter-based technology for the treatment of acute ischemic stroke, today announced two significant milestones in its mission to improve stroke care: 1) the completion of patient enrollment in its U.S. pivotal IDE clinical trial, MARRS (Millipede Aspiration for Revascularization in Stroke Study), and 2) the appointment of seasoned medtech executive Joe Rotger as Executive Vice President of Sales.
The MARRS pivotal study, conducted under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA), has successfully enrolled over 180 patients across multiple centers in the United States and Europe ahead of schedule. The study evaluates the safety and effectiveness of the Millipede 088, Perfuze's flagship Superbore aspiration catheter. Designed for rapid and complete clot removal in patients suffering from large vessel occlusion (LVO) strokes, Millipede 088 aims to improve stroke treatment outcomes and reduce procedural complexity.
'I would like to extend my sincere congratulations to all the hospitals and clinical investigators involved in the MARRS study for their exceptional commitment and collaboration throughout the trial,' said Dr. Raul Nogueira, Endowed Professor of Neurology and Neurosurgery at University of Pittsburgh School of Medicine and Principal Investigator of the MARRS Study. 'Your dedication has been instrumental in executing a rigorous and high-quality study. Most importantly, I want to express my deepest gratitude to the stroke patients and their families who participated. Their courage and generosity in the face of acute illness made this crucial research possible. The data generated from MARRS will provide important insights that have the potential to meaningfully impact the future of stroke treatment.'
'This marks a major milestone for Perfuze,' added Wayne Allen, CEO and Co-Founder of Perfuze. 'Completion of enrollment in MARRS brings us closer to making the Millipede System available to stroke physicians across the U.S. We're incredibly grateful to the investigators, clinical teams, and most importantly, the patients who participated in the study.'
Additionally, Perfuze is pleased to welcome Joe Rotger as Executive Vice President of Sales. Joe has over 25 years of commercial leadership experience in the medical device industry, with a strong focus on neurovascular technologies. He has held senior positions at prominent neurovascular organizations, including Stryker Neurovascular and Boston Scientific, where he successfully led sales teams and drove significant revenue growth.
Expressing his enthusiasm about the new role, Rotger stated, 'I am excited to join Perfuze at this critical juncture. The opportunity to introduce innovative devices such as the Millipede and Zipline catheters to the U.S. stroke market is immense, and I look forward to working with the team to make a meaningful impact on stroke care.'
Perfuze is currently in a Limited Market Release (LMR) in the United States with its FDA-cleared Millipede 088 Access Catheter, Millipede 070 Aspiration Catheter and Zipline family of delivery assist catheters. Insights from MARRS will support a future FDA submission for expanded use of the Millipede System in stroke thrombectomy.
For more information, visit
About Perfuze
Perfuze is a privately held medical device company headquartered in Galway, Ireland, dedicated to developing innovative catheter-based aspiration technology for treating acute ischemic stroke. With a mission to simplify stroke treatment, Perfuze's proprietary Millipede System delivers powerful clot retrieval performance through a simple, elegant design. The company's vision is to significantly improve clinical outcomes for stroke patients worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
New Survey Results: 94% of Investors Globally Feel Their Private Market Investments Are Behind and Need to Catch up
91% of institutional investors and wealth advisors plan to increase private market allocations, with a push for greater liquidity options, according to inaugural Private Markets Investor Survey from BBH BOSTON, June 12, 2025--(BUSINESS WIRE)--Brown Brothers Harriman (BBH) today released its first Private Markets Investor Survey, which captures the ideas and opinions about private market investments from 500 institutional investors and wealth advisors from the United States, the United Kingdom, Germany, Switzerland, and Japan. The survey finds that the majority of investors (91%) plan to increase their holdings of private markets alternatives within the next two years. This desire to increase is fueled by the fact that 94% feel they are under-exposed to private markets and need to catch up. The research finds that the reason why investors buy private markets alternatives is spread across several factors: 28% of investors believe that private markets outperform public markets and offer higher returns. Another 28% say they're most motivated by a view that these products offer protection against inflation. 23% are driven to invest based on diversification and less volatility versus public markets. 21% primarily recognize the tax efficiency offered by these products. "Although private asset strategies have seen exponential growth over the past decade, it's clear that many LPs still believe they're under-invested," says Chris Adams, Global Head of Alternative Funds Business Development at BBH. "The reasons differ among institutional and wealth types but one thing is for sure – both investor types are planning to accelerate their investments in this space." Other key findings include: Geopolitical volatility makes private markets more attractive: 78% of respondents identified that geopolitical uncertainty increases their interest in private markets alternatives. Liquidity takes center stage: The importance of liquidity and access to capital was highlighted by both investor types: 59% of all investors prefer products with a liquidity window of 4-6 years - markedly earlier than the timeline for returning investor capital in typical closed-ended commitment-based funds. 43% of investors (the highest figure) say they prioritize liquidity over target performance. Both institutional and wealth investors noted that new products offering increased liquidity would prompt them to increase their exposure to private markets. Delays in capital – A butterfly effect: 98% of investors who are already invested in private markets reported delays in having their invested capital returned. Most suggest it materially altered their investment decisions. LP education and availability: Among those who have not invested in private markets alternatives as part of their portfolios, the main reasons include availability of products (63%), knowledge about the products (57%), and long lockup periods for capital (47%). New LP capital set to enter: The 179 wealth advisors who do not currently have exposure to private markets plan to increase their exposure significantly (39%) or somewhat significantly (60%) over the next two years. ETFs rising: 34% of global investors plan to invest in an ETF with exposure to private market investments; 57% want to learn more about these products; and only 5% think it's a bad idea. Read the full report here: 2025 Brown Brothers Harriman Private Markets Investor Survey The BBH Private Markets Investor Survey was conducted by Wakefield Research ( among 500 Institutional Investors and Wealth Advisors in the following markets: U.S., UK, Japan, Switzerland, and Germany, between March 28th and April 7th, 2025, using an email invitation and an online survey. All Institutional Investors were required to have private market investments as part of their portfolio. Of the 250 wealth advisors, 71 are invested in private markets and 179 are not, but plan to in the next two years. Within each market, a 50/50 quota was set for Institutional Investors and Wealth Advisors. About Brown Brothers HarrimanBrown Brothers Harriman (BBH) is a global financial services firm known for premium service and specialist expertise. We have a 200-year track record helping clients innovate and navigate complex financial markets. Our 6,000 employees serve clients and their investments in over 90 markets across BBH's 18 offices. As a private partnership, we are uniquely built to put clients first and create success that lasts. BBH Investor Services is a leading provider of asset servicing and operating model solutions to global asset managers and financial institutions. Our asset servicing solutions include custody, global tax services, depositary and trustee, accounting, administration, transfer agency, and foreign exchange. Our operating model solutions solve platform, data, and connectivity challenges across open-architecture operating models. We support our clients' growth, enhance operational efficiency and resiliency, and streamline reporting and oversight. BBH operates in over 90 markets worldwide from 18 offices. BBH employs approximately 6,000 professionals. References to specific types of securities and asset classes are for informative purposes only and are not intended to be and should not be interpreted as recommendations. View source version on Contacts Prosek Partners (on behalf of BBH)pro-bbh@
Yahoo
31 minutes ago
- Yahoo
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples
Large-scale study aims to create comprehensive map of the human proteome to monitor changes reflecting human health and disease UPPSALA, Sweden, June 12, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease. The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC's selection of Olink Explore HT follows the platform's selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC's world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples. "We are thrilled to partner with RGC on this groundbreaking project," said Carl Raimond, president, proteomic sciences, Thermo Fisher Scientific. "The selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This important work will accelerate the pace of biomarker discovery and contribute significantly to the advancement of precision medicine." RGC is a cutting-edge research organization focused on uncovering genetic and proteomic insights, ensuring superb data stewardship, and ultimately driving scientific advancements in preventing and treating human disease. The integration of Olink Explore HT into their workflow signifies another major step forward in their commitment to leveraging multi-omics data for improved outcomes. "The Olink Explore HT platform has proven to be an invaluable tool in our pursuit of deeper biological understanding," stated John Overton, Vice President at Regeneron Genetics Center. "Its scalability and specificity are essential for handling the complexities of a project of this size. We believe this ambitious endeavor will yield transformative insights that will drive innovation in scientific discoveries." The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics, paving the way for future studies to advance our understanding of human health and disease. Learn more about Olink Explore HT. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact: Michael B. Gonzales, PhDThermo Fisher ScientificE-mail: Sign in to access your portfolio
Business Wire
34 minutes ago
- Business Wire
New Survey Results: 94% of Investors Globally Feel Their Private Market Investments Are Behind and Need to Catch up
BOSTON--(BUSINESS WIRE)--Brown Brothers Harriman (BBH) today released its first Private Markets Investor Survey, which captures the ideas and opinions about private market investments from 500 institutional investors and wealth advisors from the United States, the United Kingdom, Germany, Switzerland, and Japan. The survey finds that the majority of investors (91%) plan to increase their holdings of private markets alternatives within the next two years. This desire to increase is fueled by the fact that 94% feel they are under-exposed to private markets and need to catch up. The research finds that the reason why investors buy private markets alternatives is spread across several factors: 28% of investors believe that private markets outperform public markets and offer higher returns. Another 28% say they're most motivated by a view that these products offer protection against inflation. 23% are driven to invest based on diversification and less volatility versus public markets. 21% primarily recognize the tax efficiency offered by these products. 'Although private asset strategies have seen exponential growth over the past decade, it's clear that many LPs still believe they're under-invested,' says Chris Adams, Global Head of Alternative Funds Business Development at BBH. 'The reasons differ among institutional and wealth types but one thing is for sure – both investor types are planning to accelerate their investments in this space.' Other key findings include: Geopolitical volatility makes private markets more attractive: 78% of respondents identified that geopolitical uncertainty increases their interest in private markets alternatives. Liquidity takes center stage: The importance of liquidity and access to capital was highlighted by both investor types: 59% of all investors prefer products with a liquidity window of 4-6 years - markedly earlier than the timeline for returning investor capital in typical closed-ended commitment-based funds. 43% of investors (the highest figure) say they prioritize liquidity over target performance. Both institutional and wealth investors noted that new products offering increased liquidity would prompt them to increase their exposure to private markets. Delays in capital – A butterfly effect: 98% of investors who are already invested in private markets reported delays in having their invested capital returned. Most suggest it materially altered their investment decisions. LP education and availability: Among those who have not invested in private markets alternatives as part of their portfolios, the main reasons include availability of products (63%), knowledge about the products (57%), and long lockup periods for capital (47%). New LP capital set to enter: The 179 wealth advisors who do not currently have exposure to private markets plan to increase their exposure significantly (39%) or somewhat significantly (60%) over the next two years. ETFs rising: 34% of global investors plan to invest in an ETF with exposure to private market investments; 57% want to learn more about these products; and only 5% think it's a bad idea. Read the full report here: 2025 Brown Brothers Harriman Private Markets Investor Survey The BBH Private Markets Investor Survey was conducted by Wakefield Research ( among 500 Institutional Investors and Wealth Advisors in the following markets: U.S., UK, Japan, Switzerland, and Germany, between March 28th and April 7th, 2025, using an email invitation and an online survey. All Institutional Investors were required to have private market investments as part of their portfolio. Of the 250 wealth advisors, 71 are invested in private markets and 179 are not, but plan to in the next two years. Within each market, a 50/50 quota was set for Institutional Investors and Wealth Advisors. About Brown Brothers Harriman Brown Brothers Harriman (BBH) is a global financial services firm known for premium service and specialist expertise. We have a 200-year track record helping clients innovate and navigate complex financial markets. Our 6,000 employees serve clients and their investments in over 90 markets across BBH's 18 offices. As a private partnership, we are uniquely built to put clients first and create success that lasts. BBH Investor Services is a leading provider of asset servicing and operating model solutions to global asset managers and financial institutions. Our asset servicing solutions include custody, global tax services, depositary and trustee, accounting, administration, transfer agency, and foreign exchange. Our operating model solutions solve platform, data, and connectivity challenges across open-architecture operating models. We support our clients' growth, enhance operational efficiency and resiliency, and streamline reporting and oversight. BBH operates in over 90 markets worldwide from 18 offices. BBH employs approximately 6,000 professionals.
